WallStreetZenWallStreetZen

NASDAQ: NAMS
Newamsterdam Pharma Co Nv Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Newamsterdam Pharma Co Nv earnings were -$255.0M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest NAMS earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$41.9M, down 58.8% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, NAMS reported annual earnings of -$196.6M, with 716.5% growth.

NAMS earnings history

Current Revenue
$8.8M
Current Earnings
-$252.3M
Current Profit Margin
-2,858.3%

NAMS Return on Equity

Current Company
-57.9%
Current Industry
22.8%
Current Market
33.7%
NAMS's Return on Equity (-57.9%)... subscribe to Premium to read more.
High Return on Equity Performance

NAMS Return on Assets

Current Company
-51.1%
Current Industry
3.5%
NAMS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when NAMS announces earnings.

NAMS Return on Capital Employed

Current Company
-58.44%
Current Industry
21.3%
NAMS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NAMS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
NAMS-$254.93M-$255.01MN/A-$2.91
SNDX-$262.87M-$264.08MN/A-$3.39
ARDX-$50.48M-$65.15MN/A-$0.28
BCRX-$43.86M-$145.93MN/A-$0.73
BCYC-$153.09M-$165.37MN/A-$3.78
View Top Biotech Stocks

Newamsterdam Pharma Co Nv Earnings Reports & History FAQ

What were Newamsterdam Pharma Co Nv's earnings last quarter?

Newamsterdam Pharma Co Nv (NASDAQ: NAMS) reported Q2 2024 earnings per share (EPS) of -$0.44, up 14.53% year over year. Total NAMS earnings for the quarter were -$41.94 million. In the same quarter last year, Newamsterdam Pharma Co Nv's earnings per share (EPS) was -$0.52.

If you're new to stock investing, here's how to buy Newamsterdam Pharma Co Nv stock.

Is Newamsterdam Pharma Co Nv profitable or losing money?

As of the last Newamsterdam Pharma Co Nv earnings report, Newamsterdam Pharma Co Nv is currently losing money. Newamsterdam Pharma Co Nv's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$252.27 million, a 45.8% increase year over year.

What was NAMS's earnings growth in the past year?

As of Newamsterdam Pharma Co Nv's earnings date in Q4 2024, Newamsterdam Pharma Co Nv's earnings has grown year over year. NAMS earnings in the past year totalled -$255.01 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.